|
Nivolumab
|
28-8 rabbit (Dako)
|
1 L
|
Melanoma
|
TCs
|
Archival FFPE or new biopsy
|
5
|
58 (46,69)
|
41 (35,48)
|
Yes
|
0.001
|
Larkin J (2015) [130]
|
|
Nivolumab + ipilimumab
|
72 (60,82)
|
55 (48,62)
|
Yes
|
0.001
|
|
Nivolumab
|
≥2 L
|
5
|
44 (30,58)
|
20 (11,32)
|
Yes
|
NA
|
Weber JS (2015) [128]
|
|
Nivolumab + ipilimumab
|
1 L
|
5
|
58 (37,78)
|
55 (42,69)
|
No
|
>0.05
|
Postow MA (2015) [4]
|
|
Nivolumab
|
1 L
|
5
|
53 (41,64)
|
33 (25,42)
|
No
|
>0.05
|
Robert C (2015) [129]
|
|
≥2 L
|
NSCLC
|
TCs
|
Archival FFPE or new biopsy
|
1
|
31 (23,40)
|
9 (5,16)
|
Yes
|
0.002
|
Paz-Ares L (2015) [156]; Updated in Borghaei H (2015) [126]
|
|
5
|
36 (26,46)
|
10 (6,17)
|
Yes
|
0.002
|
|
10
|
37 (27,48)
|
11 (6,17)
|
Yes
|
0.002
|
|
≥2 L
|
Archival FFPE
|
1
|
17 (9,29)
|
17 (8,29)
|
No
|
0.9364
|
Brahmer JR (2015) [125]
|
|
5
|
21 (10,37)
|
15 (8,25)
|
No
|
0.2908
|
|
10
|
19 (8,36)
|
16 (9,26)
|
No
|
0.6411
|
|
≥2 L
|
Archival FFPE
|
1
|
20 (5,35)
|
13 (2,28)
|
No
|
>0.05
|
Rizvi NA (2015) [131]
|
|
5
|
24 (5,43)
|
14 (3,25)
|
No
|
|
1 L
|
Archival FFPE
|
5
|
31 (NA)
|
10 (NA)
|
No
|
>0.05
|
Gettinger SN (2015) [157]
|
|
Nivolumab + ipilimumab
|
1 L
|
Archival FFPE
|
5
|
19 (NA)
|
14 (NA)
|
No
|
>0.05
|
Antonia SJ (2014) [158]
|
|
Nivolumab
|
5H1 and anti-PD-1 monoclonal M3
|
≥2 L
|
Archival FFPE
|
5
|
39 (34,44)
|
6 (1,12)
|
Yes
|
0.025
|
Taube JM (2014) [113]
|
|
Pembrolizumab
|
22C3 mouse (Dako)
|
≥1 L
|
NSCLC
|
TCs and ICs
|
New biopsy
|
50
|
45 (33,57)
|
17 (10,25)
|
Yes
|
0.001
|
Garon EB (2015) [5]
|
|
1 L
|
New biopsy
|
50
|
47 (23,72)
|
19 (8,38)
|
Yes
|
NA
|
Rival NA (2015) [159]
|
|
Any
|
Archival FFPE
|
1
|
25 (NA)
|
13 (NA)
|
Yes
|
NA
|
Garon EB (2014) [160]
|
|
≥1 L
|
Archival FFPE
|
50
|
30 (23,39)
|
9.8 (NA)
|
Yes
|
NA
|
Herbst RS (2015) [140]
|
|
29 (22,37)
|
10.7 (NA)
|
|
1 L
|
Archival FFPE
|
50
|
16 (NA)
|
10 (NA)
|
Yes
|
NA
|
Garon EB (2014) [161]
|
|
Atezolizumab (MPDL3280A)
|
SP142 rabbit (Roche Ventana)
|
≥2 L
|
NSCLC
|
TCs and ICs
|
Archival FFPE and new biopsy
|
50
|
45 (23,68)
|
14 (6,25)
|
Yes
|
NA
|
Leora H (2015) [162]
|
|
≥2 L
|
NSCLC
|
1+
|
31 (25,37)
|
20 (14,26)
|
Yes
|
0.015
|
Herbst RS (2014) [145]
|
|
Solid Tumor
|
1+
|
29 (27,31)
|
13 (10,16)
|
Yes
|
0.007
|
|
≥2 L
|
NSCLC
|
2+
|
18 (NA)
|
8 (NA)
|
Yes
|
NA
|
Spira AI (2015) [143]
|
|
Durvalumab (MEDI-4736)
|
SP263 rabbit (Roche Ventana)
|
≥2 L
|
NSCLC
|
TCs
|
Archival FFPE and new biopsy
|
25
|
39 (NA)
|
5 (NA)
|
Yes
|
NA
|
Segal NH (2014) [163]
|
|
33 (13,59)
|
30 (16,47)
|
No for combo
|
NA
|
Antonia SJ (2016) [155];
|
|
22 (3, 60)
|
29 (8, 58)
|
No for monotherapy
|
NA
|
